Published in Circ Res on January 08, 2010
Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med (2011) 5.77
Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov (2011) 1.65
Opportunities for use of human iPS cells in predictive toxicology. Clin Pharmacol Ther (2011) 1.28
How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol (2011) 1.19
Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation (2012) 1.14
Clinical cardiac safety profile of nilotinib. Haematologica (2012) 1.13
Novel role for p90 ribosomal S6 kinase in the regulation of cardiac myofilament phosphorylation. J Biol Chem (2010) 1.05
Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. Oncologist (2010) 1.04
Bacterial serine/threonine protein kinases in host-pathogen interactions. J Biol Chem (2014) 1.00
Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma. Oncogene (2011) 0.98
A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ Res (2011) 0.98
Spatial cycles in G-protein crowd control. EMBO J (2010) 0.96
Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. Oncologist (2014) 0.94
Mitochondria death/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies. Biochem Res Int (2012) 0.86
Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis. Int J Clin Oncol (2012) 0.83
Phosphoinositide 3-kinase (PI3K(p110alpha)) directly regulates key components of the Z-disc and cardiac structure. J Biol Chem (2011) 0.82
Osteopontin: At the cross-roads of myocyte survival and myocardial function. Life Sci (2014) 0.82
Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs. Biomed Res Int (2015) 0.81
Roadmap for biomarkers of cancer therapy cardiotoxicity. Heart (2015) 0.81
Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma. Cancer Cell Int (2014) 0.81
Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged Sword. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2013) 0.79
Sarcomas of the heart as a difficult interdisciplinary problem. Arch Med Sci (2014) 0.79
Aspects of eukaryotic-like signaling in Gram-positive cocci: a focus on virulence. Future Microbiol (2011) 0.79
Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. Heart Fail Rev (2015) 0.79
Targeted therapies in breast cancer: are heart and vessels also being targeted? Breast Cancer Res (2012) 0.79
Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue. PLoS One (2016) 0.78
Cancer chemotherapy induces cardiotoxicity by targeting cardiac stem cells. J Cell Mol Med (2010) 0.78
A chrysin derivative suppresses skin cancer growth by inhibiting cyclin-dependent kinases. J Biol Chem (2013) 0.78
A Novel Phosphopeptide Microarray Based Interactome Map in Breast Cancer Cells Reveals Phosphoprotein-GRB2 Cell Signaling Networks. PLoS One (2013) 0.78
Imatinib activates pathological hypertrophy by altering myocyte calcium regulation. Clin Transl Sci (2014) 0.77
Computer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunities. Int J Mol Sci (2014) 0.77
Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma. Hepat Med (2010) 0.77
Relationship between clinical data and gene expression in the HER2/ErbB2-dependent signaling pathway in patients with acute heart failure. J Appl Genet (2013) 0.76
Cardio-oncology: Concepts and practice. Indian Heart J (2016) 0.75
HDACs and hypertrophy, kinases and cancer. Circulation (2011) 0.75
Cardiotoxicity associated with targeted cancer therapies. Mol Clin Oncol (2016) 0.75
Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives. Cureus (2017) 0.75
Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. Oncologist (2017) 0.75
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med (2006) 9.07
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet (2007) 6.76
Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest (2005) 4.31
Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev (2010) 2.68
c-Jun N-terminal kinases mediate reactivation of Akt and cardiomyocyte survival after hypoxic injury in vitro and in vivo. Circ Res (2005) 2.23
Cyclophilin D controls mitochondrial pore-dependent Ca(2+) exchange, metabolic flexibility, and propensity for heart failure in mice. J Clin Invest (2010) 2.12
Stabilization of beta-catenin by a Wnt-independent mechanism regulates cardiomyocyte growth. Proc Natl Acad Sci U S A (2003) 2.01
Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation (2008) 1.84
Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J Clin Invest (2008) 1.76
17beta-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ Res (2004) 1.74
Glycogen-Synthase Kinase3beta/beta-catenin axis promotes angiogenesis through activation of vascular endothelial growth factor signaling in endothelial cells. Circ Res (2005) 1.56
Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heart. Sci Transl Med (2013) 1.55
Integrin-linked kinase regulates endothelial cell survival and vascular development. Mol Cell Biol (2004) 1.46
The beta-catenin/T-cell factor/lymphocyte enhancer factor signaling pathway is required for normal and stress-induced cardiac hypertrophy. Mol Cell Biol (2006) 1.41
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2011) 1.40
CCM3/PDCD10 stabilizes GCKIII proteins to promote Golgi assembly and cell orientation. J Cell Sci (2010) 1.35
Glycogen synthase kinase-3beta regulates post-myocardial infarction remodeling and stress-induced cardiomyocyte proliferation in vivo. Circ Res (2010) 1.33
Glycogen synthase kinase-3beta regulates growth, calcium homeostasis, and diastolic function in the heart. J Biol Chem (2004) 1.33
Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci (2009) 1.28
Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res (2013) 1.27
GSK-3α is a central regulator of age-related pathologies in mice. J Clin Invest (2013) 1.25
Stretch-induced IL-8 depends on c-Jun NH2-terminal and nuclear factor-kappaB-inducing kinases. Am J Physiol Lung Cell Mol Physiol (2003) 1.24
CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle (2012) 1.20
GSK-3alpha directly regulates beta-adrenergic signaling and the response of the heart to hemodynamic stress in mice. J Clin Invest (2010) 1.15
Wnt signaling exerts an antiproliferative effect on adult cardiac progenitor cells through IGFBP3. Circ Res (2011) 1.13
Glycogen synthase kinase-3α limits ischemic injury, cardiac rupture, post-myocardial infarction remodeling and death. Circulation (2011) 1.09
Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival. J Biol Chem (2003) 1.07
Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. Eur Heart J (2013) 1.06
Serine 58 of 14-3-3zeta is a molecular switch regulating ASK1 and oxidant stress-induced cell death. Mol Cell Biol (2009) 1.06
Deletion of cytosolic phospholipase A2 promotes striated muscle growth. Nat Med (2003) 1.05
Helix-loop-helix protein p8, a transcriptional regulator required for cardiomyocyte hypertrophy and cardiac fibroblast matrix metalloprotease induction. Mol Cell Biol (2006) 1.04
17 Beta-estradiol differentially affects left ventricular and cardiomyocyte hypertrophy following myocardial infarction and pressure overload. J Card Fail (2008) 1.02
Targeting GSK-3 family members in the heart: a very sharp double-edged sword. J Mol Cell Cardiol (2010) 1.01
Targeted deletion of integrin-linked kinase reveals a role in T-cell chemotaxis and survival. Mol Cell Biol (2005) 1.01
The GCK II and III subfamilies of the STE20 group kinases. Front Biosci (2007) 1.00
p38 mitogen-activated protein kinase: a future target for heart failure therapy? J Am Coll Cardiol (2006) 0.99
Renal ischemia/reperfusion and ATP depletion/repletion in LLC-PK(1) cells result in phosphorylation of FKHR and FKHRL1. Kidney Int (2003) 0.99
A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ Res (2011) 0.98
A novel cardioprotective p38-MAPK/mTOR pathway. Exp Cell Res (2011) 0.96
SOK1 translocates from the Golgi to the nucleus upon chemical anoxia and induces apoptotic cell death. J Biol Chem (2008) 0.94
Inhibition of oncogenic K-ras signaling by aerosolized gene delivery in a mouse model of human lung cancer. Clin Cancer Res (2002) 0.93
Gene 33/RALT is induced by hypoxia in cardiomyocytes, where it promotes cell death by suppressing phosphatidylinositol 3-kinase and extracellular signal-regulated kinase survival signaling. Mol Cell Biol (2006) 0.93
Activation of beta-catenin signaling pathways by classical G-protein-coupled receptors: mechanisms and consequences in cycling and non-cycling cells. Cell Cycle (2006) 0.92
Glycogen synthase kinase-3beta -- actively inhibiting hypertrophy. Trends Cardiovasc Med (2007) 0.90
Cancer genetics and the cardiotoxicity of the therapeutics. J Am Coll Cardiol (2013) 0.88
Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog Cardiovasc Dis (2010) 0.87
Differential activation of cultured neonatal cardiomyocytes by plasmalemmal versus intracellular G protein-coupled receptor 55. J Biol Chem (2013) 0.87
Role of integrin-linked kinase in leukocyte recruitment. J Biol Chem (2002) 0.87
Not all hypertrophy is created equal. Circ Res (2007) 0.84
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J (2012) 0.83
A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA. Am J Cancer Ther Pharmacol (2014) 0.82
Developing small molecules to inhibit kinases unkind to the heart: p38 MAPK as a case in point. Drug Discov Today Dis Mech (2010) 0.82
Double-edged sword of the new cancer therapeutics. Circulation (2012) 0.80
Cytosolic phospholipase A(2)α protects against ischemia/reperfusion injury in the heart. Clin Transl Sci (2011) 0.80
Cardiotoxicity due to cancer therapy. Tex Heart Inst J (2011) 0.79
Mechanism-based engineering against anthracycline cardiotoxicity. Circulation (2013) 0.79
Apoptosis signal-regulating kinase/nuclear factor-kappaB: a novel signaling pathway regulates cardiomyocyte hypertrophy. Circulation (2002) 0.78
Recent insights into cardiac hypertrophy and left ventricular remodeling. Curr Heart Fail Rep (2006) 0.78
Focusing the spotlight on GSK-3 in aging. Aging (Albany NY) (2013) 0.77
The weakness of a big heart. Nat Med (2008) 0.77
Imatinib activates pathological hypertrophy by altering myocyte calcium regulation. Clin Transl Sci (2014) 0.77
Troponin I-interacting protein kinase: a novel cardiac-specific kinase, emerging as a molecular target for the treatment of cardiac disease. Circ J (2014) 0.75
The Heart Failure Society of America in 2020: a vision for the future. J Card Fail (2012) 0.75
The year in heart failure 2005. J Card Fail (2006) 0.75
Highlights of the 2004 scientific sessions of the Heart Failure Society of America, Toronto, Canada, September 12 to 15, 2004. J Am Coll Cardiol (2005) 0.75
Highlights of the 2003 scientific sessions of the Heart Failure Society of America; Las Vegas, Nevada, September 21 to 24, 2003. J Am Coll Cardiol (2004) 0.75